MedTrace Logo

Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?

NCT04757272 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2106

Last updated 2022-09-30

No results posted yet for this study

Summary

Modulation of the renin angiotensin system by the chronic hepatitis C virus treatment either by (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.

Conditions

  • Corona Virus Infection
  • Hepatitis

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2022-03-30
Completion
2022-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04757272 on ClinicalTrials.gov